Gynecologic Cancer News

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.

CHICAGO — Assessment of RUBY trial outcomes by blinded independent central review confirmed the benefits of adding dostarlimab to chemotherapy for women with primary advanced or recurrent endometrial cancer.

CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.

CHICAGO — Pelvic node dissection and simple hysterectomy appeared noninferior to radical hysterectomy at 3 years among women with early-stage, low-risk cervical cancer, according to data from the SHAPE study.

A recent study of trends in HPV vaccine hesitancy found that the number of parents citing safety concerns as a reason not to vaccinate their children has increased.

Metabolically healthy and unhealthy obesity appeared associated with increased risk for various obesity-associated cancer types, according to study results presented at European Congress on Obesity.

A smartphone app-assisted postoperative monitoring intervention improved quality of recovery after cancer surgery, according to results of a study conducted at University of Calgary.

The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.

The addition of pembrolizumab to chemotherapy, with or without bevacizumab, significantly extended OS and PFS among women with persistent, recurrent or metastatic cervical cancer, according to data from the KEYNOTE-826 study.

Staffing shortages at radiation oncology clinics are causing treatment delays and increased patient anxiety, according to results of a national survey from American Society for Radiation Oncology.